{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:36:43Z","timestamp":1795120603402,"version":"4.10.3"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by intrahepatic accumulation and is closely associated with metabolic problems. Some studies have indicated that Chaihu-Shugan-San (CSS) may have a positive effect on NAFLD, but robust evidence-based research to substantiate the application of CSS is scarce. A meta-analysis was conducted to assess the clinical efficacy and safety of CSS in the treatment for NAFLD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The literature reporting CSS in NAFLD was searched from inception to October 2023 in in 7 Chinese or English databases. Studies were screened and incorporated based on predefined criteria. Data were extracted and quality was assessed independently by 2 researchers according to the Cochrane risk of bias tools. The changes in outcomes were analyzed using the mean difference (MD) and 95% confidence intervals (CIs) with a random- or fixed-effects model to examine the effect of CSS. RevMan5.4 software was used to perform meta-analyses, and the meta package of R 4.0.0 software was used for publication bias analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total 17 studies involving 1576 participants were screened for meta-analysis. There was high heterogeneity among studies for all continuous outcomes. Compared with common treatments, CSS could decrease aspartate-aminotransferase (MD\u2005=\u2005\u221212.02, 95% CI [\u221215.97, \u22128.07]), alanine-aminotransferase (MD\u2005=\u2005\u221210.89, 95% CI [\u221216.35, \u22125.43]), triglyceride and total cholesterol levels. In addition, CSS may increase the high-density lipoprotein cholesterol levels. And, CSS was associated with a lower incidence of adverse events (RR\u2005=\u20050.79, 95% CI [0.33, 1.91]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Current evidence shows that single or combined use of CSS is effective for NAFLD liver enzymes and blood lipids. Nevertheless, it is challenging to reach a conclusive determination owing to significant heterogeneity and ambiguous risk of bias in some trials. Therefore, more high-quality evidence is required for the clinical implementation of CSS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042303","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T22:18:34Z","timestamp":1746483514000},"page":"e42303","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Chaihu-Shugan-San for patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Xiangke","family":"Qu","sequence":"first","affiliation":[{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"},{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Sun","sequence":"additional","affiliation":[{"name":"Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shen","sequence":"additional","affiliation":[{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Dong","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofa","family":"Li","sequence":"additional","affiliation":[{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Ma","sequence":"additional","affiliation":[{"name":"Academic Research Department, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6074-5669","authenticated-orcid":false,"given":"Jinhui","family":"Sun","sequence":"additional","affiliation":[{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250513","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"R2-20250513","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 a global public health perspective.","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R3-20250513","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep4.1387","article-title":"Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease.","volume":"3","author":"Golabi","year":"2019","journal-title":"Hepatol Commun"},{"key":"R4-20250513","doi-asserted-by":"crossref","first-page":"e076388","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study.","volume":"384","author":"Kim","year":"2024","journal-title":"BMJ"},{"key":"R5-20250513","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R6-20250513","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD From 1999 to 2018 in China.","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"R7-20250513","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease.","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"R8-20250513","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors.","volume":"18","author":"Juanola","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R9-20250513","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis.","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"R10-20250513","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"R11-20250513","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2020.07.034","article-title":"Progression of fatty liver disease in children receiving standard of care lifestyle advice.","volume":"159","author":"Xanthakos","year":"2020","journal-title":"Gastroenterology"},{"key":"R12-20250513","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3350\/cmh.2016.0049","article-title":"Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.","volume":"22","author":"Oh","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"R13-20250513","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R14-20250513","doi-asserted-by":"crossref","first-page":"107398","DOI":"10.1016\/j.phrs.2024.107398","article-title":"The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials.","volume":"208","author":"Musazadeh","year":"2024","journal-title":"Pharmacol Res"},{"key":"R15-20250513","doi-asserted-by":"crossref","first-page":"880014","DOI":"10.3389\/fnut.2022.880014","article-title":"Effects of synbiotics, probiotics, and prebiotics on liver enzymes of patients with non-alcoholic fatty liver disease: a systematic review and network meta-analysis.","volume":"9","author":"Kanchanasurakit","year":"2022","journal-title":"Front Nutr"},{"key":"R16-20250513","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1016\/j.apsb.2022.05.001","article-title":"Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: a promising drug Potentilla discolor Bunge.","volume":"12","author":"Ji","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"R17-20250513","first-page":"1004","article-title":"Systematic evaluation and meta analysis on nonalcoholic fatty liver disease treated with Chaihu Shugan San.","volume":"9","author":"Zhang","year":"2014","journal-title":"World J Integr Tradit West Med"},{"issue":"Pt A","key":"R18-20250513","doi-asserted-by":"crossref","first-page":"116967","DOI":"10.1016\/j.jep.2023.116967","article-title":"Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.","volume":"318","author":"Zheng","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"R19-20250513","doi-asserted-by":"crossref","first-page":"967623","DOI":"10.3389\/fphar.2022.967623","article-title":"Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: a network pharmacology study and in vivo experimental validation.","volume":"13","author":"Lei","year":"2022","journal-title":"Front Pharmacol"},{"key":"R20-20250513","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11655-016-2252-4","article-title":"Protective effects of chaihu shugan san () on nonalcoholic fatty liver disease in rats with insulin resistance.","volume":"24","author":"Jiang","year":"2018","journal-title":"Chin J Integr Med"},{"key":"R21-20250513","doi-asserted-by":"crossref","first-page":"9390786","DOI":"10.1155\/2018\/9390786","article-title":"Chaihu-Shugan-San Decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD rats via the NLRP3 inflammasome pathway.","volume":"2018","author":"Liang","year":"2018","journal-title":"Evid Based Complement Alternat Med"},{"key":"R22-20250513","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R23-20250513","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R24-20250513","first-page":"2010","article-title":"Clinical observation of Chaihu Shugan San in the treatment of 82 cases of non-alcoholic fatty liver.","volume":"20","author":"Pan","year":"2009","journal-title":"Lishizhen Med Materia Medica Res"},{"key":"R25-20250513","first-page":"47","article-title":"Chaihu Shugan powder on treating 55 cases of fatty liver.","volume":"24","author":"Shi","year":"2010","journal-title":"J Pract Tradit Chin Intern Med"},{"key":"R26-20250513","first-page":"1129","article-title":"Clinical investigation of Chaihu shugan san on non-alcoholic fatty liver.","volume":"32","author":"Wang","year":"2010","journal-title":"Hebei J Tradit Chin Med"},{"key":"R27-20250513","first-page":"1299","article-title":"Efficacy of combined treatment of traditional Chinese medicine and western medicine for non-alcoholic fatty liver disease.","volume":"18","author":"Teng","year":"2011","journal-title":"Chin J Prim Med Pharm"},{"key":"R28-20250513","first-page":"640","article-title":"Chaiyue Decoction for 81 cases with nonalcoholic fatty liver.","volume":"31","author":"Miao","year":"2012","journal-title":"Shandong J Tradit Chin Med"},{"key":"R29-20250513","first-page":"90","article-title":"Clinical observation on therapeutic effect of Chaihu Shugan San in Treating non-alcoholic fatty liver.","volume":"11","author":"Zhang","year":"2013","journal-title":"Chin Med Modern Distance Educ China"},{"key":"R30-20250513","first-page":"746","article-title":"Observation on therapeutic effect of Chaihu Shugan San in Treating Nonalcoholic Fatty Liver Disease.","volume":"30","author":"Cao","year":"2015","journal-title":"Guangming J Chin Med"},{"key":"R31-20250513","first-page":"344","article-title":"Combining traditional Chinese and western medicine for nonalcoholic fatty liver diseases with liver qi stagnation syndrome.","volume":"32","author":"Fang","year":"2016","journal-title":"J Pract Tradit Chin Med"},{"key":"R32-20250513","first-page":"1998","article-title":"Effect of Chaihu Shugan powder combined with Exenatide on quantitative index of total liver fat in patients with non-alcoholic fatty liver disease.","volume":"15","author":"Tan","year":"2018","journal-title":"Laborat Med Clin"},{"key":"R33-20250513","first-page":"56","article-title":"Clinical study on Chaihu Shugan Powder in treating non-alcoholic fatty liver.","volume":"28","author":"Zhu","year":"2018","journal-title":"Shenzhen J Integr Tradit Chin West Med"},{"key":"R34-20250513","first-page":"35","article-title":"The clinical effect of Chaihu-Shugan powder on nonalcoholic fatty liver based on FibroScan Technology.","volume":"13","author":"Huang","year":"2020","journal-title":"J Qingyuan Polytech"},{"key":"R35-20250513","first-page":"187","article-title":"Clinical study on the effect of Chaihu Shugan Powder for non-alcoholic steatohepatitis inflammatory factors.","volume":"37","author":"Luo","year":"2020","journal-title":"Tianjin J Tradit Chin Med"},{"key":"R36-20250513","first-page":"24","article-title":"Clinical study on modified Chaihu Shugan powder combined with Polyene phosphati-dylcholine capsules for non-alcoholic steatohepatitis.","volume":"53","author":"Lei","year":"2021","journal-title":"J New Chin Med"},{"key":"R37-20250513","first-page":"8","article-title":"Clinical effect of Chaihu Shuan powder for patients with non-alcoholic fatty liver.","volume":"21","author":"Su","year":"2021","journal-title":"Pract Clin J Integr Tradit Chin West Med"},{"key":"R38-20250513","first-page":"129","article-title":"Liver with Liver Stagnation and Spleen Deficiency Syndrome and intestinal microflora.","volume":"27","author":"Xie","year":"2021","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"R39-20250513","first-page":"3194","article-title":"Observation on the clinical effect of Ezetimibe Combined with Chaihu Shugan Pill in the treatment of nonalcoholic fatty liver disease.","volume":"37","author":"Chen","year":"2022","journal-title":"Guangming J Chin Med"},{"key":"R40-20250513","first-page":"221","article-title":"Therapeutic effect and mechanism of Chaihu Shugansan on nonalcoholic fatty liver disease.","volume":"24","author":"He","year":"2022","journal-title":"J North China Univ Sci Technol"},{"key":"R41-20250513","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.3748\/wjg.v30.i43.4597","article-title":"Potential of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease: a promising future.","volume":"30","author":"Zhang","year":"2024","journal-title":"World J Gastroenterol"},{"key":"R42-20250513","doi-asserted-by":"crossref","first-page":"1499602","DOI":"10.3389\/fphar.2024.1499602","article-title":"Application and mechanism of Chinese herb medicine in the treatment of non-alcoholic fatty liver disease.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R43-20250513","doi-asserted-by":"crossref","first-page":"e38668","DOI":"10.1097\/MD.0000000000038668","article-title":"Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: an updated systematic review and meta-analysis.","volume":"103","author":"Zhang","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R44-20250513","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jep.2013.01.029","article-title":"Chaihu-Shugan-San, an oriental herbal preparation, for the treatment of chronic gastritis: a meta-analysis of randomized controlled trials.","volume":"146","author":"Qin","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"R45-20250513","doi-asserted-by":"crossref","first-page":"117659","DOI":"10.1016\/j.jep.2023.117659","article-title":"Effect of Chaihu-Shugan-San on functional dyspepsia and gut microbiota: a randomized, double-blind, placebo-controlled trial.","volume":"322","author":"Wang","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"R46-20250513","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.1038\/s41598-024-79100-z","article-title":"Association of depression with severe non-alcoholic fatty liver disease: evidence from the UK Biobank study and Mendelian randomization analysis.","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci Rep"},{"key":"R47-20250513","doi-asserted-by":"crossref","first-page":"691696","DOI":"10.3389\/fmed.2021.691696","article-title":"Is fatty liver associated with depression? A meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease.","volume":"8","author":"Xiao","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R48-20250513","doi-asserted-by":"crossref","first-page":"1357664","DOI":"10.3389\/fendo.2024.1357664","article-title":"Non-alcoholic fatty liver disease and coexisting depression, anxiety and\/or stress in adults: a systematic review and meta-analysis.","volume":"15","author":"Shea","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R49-20250513","doi-asserted-by":"crossref","first-page":"BSR20221030","DOI":"10.1042\/BSR20221030","article-title":"Exploring mechanisms of Chaihu-Shugan-San against liver fibrosis by integrated multi-omics and network pharmacology approach.","volume":"42","author":"Xie","year":"2022","journal-title":"Biosci Rep"},{"key":"R50-20250513","doi-asserted-by":"crossref","first-page":"e18211","DOI":"10.1111\/jcmm.18211","article-title":"Integrated analyses for identification of a three-gene signature associated with Chaihu Shugan San formula for hepatocellular carcinoma treatment.","volume":"28","author":"Xing","year":"2024","journal-title":"J Cell Mol Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:04:10Z","timestamp":1747173850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":50,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042303","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}